{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:37Z","timestamp":1772166577620,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023M733240"],"award-info":[{"award-number":["2023M733240"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100016305","name":"First Affiliated Hospital of Zhengzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016305","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Project of Henan Medical Science and Technology Research Plan","award":["SBGJ202101007"],"award-info":[{"award-number":["SBGJ202101007"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81830005"],"award-info":[{"award-number":["81830005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-041"],"award-info":[{"award-number":["2021-I2M-1-041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several approaches are being explored for engineering off-the-shelf chimeric antigen receptor (CAR) T cells. In this study, we engineered chimeric Fc\u03b3 receptor (Fc\u03b3R) T cells and tested their potential as a versatile platform for universal T cell therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Chimeric Fc\u03b3R (CFR) constructs were generated using three distinct forms of Fc\u03b3R, namely CD16A, CD32A, and CD64. The functionality of CFR T cells was evaluated through degranulation assays, specific target lysis experiments, in vitro cytokine production analysis, and assessment of tumor xenograft destruction specificity in mouse models using different monoclonal antibodies (MoAbs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three types of CFR T cells were engineered, 16s3, 32-8a, 64-8a CFR T cells. In the presence of rituximab (RTX), cytotoxicity of all three types of CFR T cells against CD20\n                      <jats:sup>+<\/jats:sup>\n                      Raji-wt, K562-CD20\n                      <jats:sup>+<\/jats:sup>\n                      , and primary tumor cells was significantly higher than that of the mock T cells (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). When herceptin was used, all three types of CFR T cells exhibited significant cytotoxicity against HER2\n                      <jats:sup>+<\/jats:sup>\n                      cell lines of SK-BR-3, SK-OV-3, and HCC1954 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). The cytotoxicity of 64-8a CFR T cells was significantly inhibited by free human IgG at a physiological dose (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), which was not observed in 16s3, 32-8a CFR T cells. Compared to 32-8a CFR T cells, 16s3 CFR T cells exhibited more prolonged cytotoxicity than 32-8a CFR T cells (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). In in vivo assays using xenograft models, 16s3 CFR T cells significantly prolonged the survival of mice xenografted with Raji-wt cells in the presence of RTX (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), and effectively reduced tumor burden in mice xenografted with SK-OV-3 cells in the presence of herceptin (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05). No significant non-specific cytotoxicity of CFR T cells was found in vivo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The anti-tumor effects of the CFR T cells in vitro and in xenograft mouse models are mediated by specific MoAbs such as RTX and herceptin. The CFR T cells therefore have the features of universal T cells with specificity directed by MoAbs. 16s3 CFR T cells are chosen for clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40164-025-00595-x","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T22:40:51Z","timestamp":1736894451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction and characterization of chimeric Fc\u03b3R T cells for universal T cell therapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Juanjuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongqun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongxing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"8","key":"595_CR1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u201333.","journal-title":"N Engl J Med"},{"issue":"11","key":"595_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"issue":"1","key":"595_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","volume":"17","author":"J Xu","year":"2024","unstructured":"Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, Chen LJ, Hou J, Chen Z, Zhao WH, He AL, Mi JQ, Chen SJ. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024;17(1):23.","journal-title":"J Hematol Oncol"},{"key":"595_CR4","doi-asserted-by":"crossref","unstructured":"Zhao J, Ren Q, Liu X, Guo X, Song Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. J Hematol Oncol 2023, 16(1):92.","DOI":"10.1186\/s13045-023-01489-3"},{"issue":"1","key":"595_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-023-01488-4","volume":"16","author":"X Liu","year":"2023","unstructured":"Liu X, Zhao J, Guo X, Song Y. CD20 x CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting. J Hematol Oncol. 2023;16(1):90.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"595_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","volume":"13","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y. CAR-T cell combination therapies in hematologic malignancies. Exp Hematol Oncol. 2024;13(1):69.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"595_CR7","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-024-01633-7","volume":"17","author":"W Zhang","year":"2024","unstructured":"Zhang W, Huang X. In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy. J Hematol Oncol. 2024;17(1):110.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"595_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","volume":"12","author":"K Zhu","year":"2024","unstructured":"Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024;12(1):16.","journal-title":"Biomark Res"},{"issue":"26","key":"595_CR9","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernandez-Rivas JA, Hong X, Kim SJ, Lewis D, Mishima Y, Ozcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022;386(26):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"8","key":"595_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Simkovic M, Shadman M, Osterborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trneny M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031\u201343.","journal-title":"Lancet Oncol"},{"issue":"1","key":"595_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, et al. Trastuzumab Deruxtecan in previously treated HER2-Low advanced breast Cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"key":"595_CR12","doi-asserted-by":"crossref","unstructured":"Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-Engineering for Modulated Effector functions-improving antibodies for Cancer Treatment. Antibodies (Basel) 2020, 9(4).","DOI":"10.3390\/antib9040064"},{"issue":"4","key":"595_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/imcb.12326","volume":"98","author":"AM Chenoweth","year":"2020","unstructured":"Chenoweth AM, Wines BD, Anania JC, Mark Hogarth P. Harnessing the immune system via FcgammaR function in immune therapy: a pathway to next-gen mAbs. Immunol Cell Biol. 2020;98(4):287\u2013304.","journal-title":"Immunol Cell Biol"},{"issue":"18","key":"595_CR14","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","volume":"81","author":"LC Tsao","year":"2021","unstructured":"Tsao LC, Force J, Hartman ZC. Mechanisms of Therapeutic Antitumor Monoclonal antibodies. Cancer Res. 2021;81(18):4641\u201351.","journal-title":"Cancer Res"},{"issue":"15","key":"595_CR15","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","volume":"185","author":"PJ Carter","year":"2022","unstructured":"Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185(15):2789\u2013805.","journal-title":"Cell"},{"issue":"10","key":"595_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41577-020-00410-0","volume":"20","author":"S Bournazos","year":"2020","unstructured":"Bournazos S, Gupta A, Ravetch JV. The role of IgG fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020;20(10):633\u201343.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"595_CR17","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1038\/s41467-021-24591-x","volume":"12","author":"V Mysore","year":"2021","unstructured":"Mysore V, Cullere X, Mears J, Rosetti F, Okubo K, Liew PX, Zhang F, Madera-Salcedo I, Rosenbauer F, Stone RM, Aster JC, von Andrian UH, Lichtman AH, Raychaudhuri S, Mayadas TN. FcgammaR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity. Nat Commun. 2021;12(1):4791.","journal-title":"Nat Commun"},{"key":"595_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molimm.2021.07.024","volume":"139","author":"C Macri","year":"2021","unstructured":"Macri C, Morgan H, Villadangos JA, Mintern JD. Regulation of dendritic cell function by Fc-gamma-receptors and the neonatal fc receptor. Mol Immunol. 2021;139:193\u2013201.","journal-title":"Mol Immunol"},{"key":"595_CR19","doi-asserted-by":"crossref","unstructured":"Forest-Nault C, Gaudreault J, Henry O, Durocher Y, De Crescenzo G. On the Use of Surface Plasmon Resonance Biosensing to understand IgG-FcgammaR interactions. Int J Mol Sci 2021, 22(12).","DOI":"10.3390\/ijms22126616"},{"issue":"9","key":"595_CR20","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1172\/JCI130029","volume":"129","author":"TT Wang","year":"2019","unstructured":"Wang TT, Ravetch JV. Functional diversification of IgGs through fc glycosylation. J Clin Invest. 2019;129(9):3492\u20138.","journal-title":"J Clin Invest"},{"issue":"1","key":"595_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/imr.12365","volume":"268","author":"JM Caaveiro","year":"2015","unstructured":"Caaveiro JM, Kiyoshi M, Tsumoto K. Structural analysis of Fc\/FcgammaR complexes: a blueprint for antibody design. Immunol Rev. 2015;268(1):201\u201321.","journal-title":"Immunol Rev"},{"issue":"1","key":"595_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/imr.12342","volume":"268","author":"LN Dahal","year":"2015","unstructured":"Dahal LN, Roghanian A, Beers SA, Cragg MS. FcgammaR requirements leading to successful immunotherapy. Immunol Rev. 2015;268(1):104\u201322.","journal-title":"Immunol Rev"},{"issue":"4956","key":"595_CR23","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1126\/science.2139735","volume":"248","author":"WQ Qiu","year":"1990","unstructured":"Qiu WQ, de Bruin D, Brownstein BH, Pearse R, Ravetch JV. Organization of the human and mouse low-affinity fc gamma R genes: duplication and recombination. Science. 1990;248(4956):732\u20135.","journal-title":"Science"},{"issue":"4","key":"595_CR24","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1084\/jem.170.4.1369","volume":"170","author":"DG Brooks","year":"1989","unstructured":"Brooks DG, Qiu WQ, Luster AD, Ravetch JV. Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. J Exp Med. 1989;170(4):1369\u201385.","journal-title":"J Exp Med"},{"issue":"10","key":"595_CR25","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/1535-7163.MCT-19-0003","volume":"19","author":"H Lu","year":"2020","unstructured":"Lu H, Molony RD, Chen D, Jang S, Wolf B, Ewert S, Flaherty M, Xu F, Isim S, Shim Y, Dornelas C, Balke N, Leber XC, Scharenberg M, Koelln J, Choi E, Ward R, Johnson J, Calzascia T, Isnardi I, Williams JA, Lindenbergh PL, van de Donk N, Mutis T, Huet H, Lees E, Meyer MJ. Development of Anti-CD32b antibodies with enhanced fc function for the treatment of B and plasma cell malignancies. Mol Cancer Ther. 2020;19(10):2089\u2013104.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"595_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12341","volume":"268","author":"CE Hargreaves","year":"2015","unstructured":"Hargreaves CE, Rose-Zerilli MJ, Machado LR, Iriyama C, Hollox EJ, Cragg MS, Strefford JC. Fcgamma receptors: genetic variation, function, and disease. Immunol Rev. 2015;268(1):6\u201324.","journal-title":"Immunol Rev"},{"issue":"3","key":"595_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1182\/blood.V99.3.754","volume":"99","author":"G Cartron","year":"2002","unstructured":"Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754\u20138.","journal-title":"Blood"},{"issue":"21","key":"595_CR28","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","volume":"21","author":"WK Weng","year":"2003","unstructured":"Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to Rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21):3940\u20137.","journal-title":"J Clin Oncol"},{"issue":"11","key":"595_CR29","doi-asserted-by":"publisher","first-page":"e1235108","DOI":"10.1080\/2162402X.2016.1235108","volume":"5","author":"N Siebert","year":"2016","unstructured":"Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Juttner M, Ehlert K, Kietz S, Muller I, Lode HN. Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18\/CHO show higher ADCC levels and improved event-free survival. Oncoimmunology. 2016;5(11):e1235108.","journal-title":"Oncoimmunology"},{"issue":"11","key":"595_CR30","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1002\/cam4.1819","volume":"7","author":"D Shepshelovich","year":"2018","unstructured":"Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O\u2019Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Med. 2018;7(11):5478\u201387.","journal-title":"Cancer Med"},{"issue":"3","key":"595_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/2326-6066.CIR-13-0099-T","volume":"2","author":"F Ochi","year":"2014","unstructured":"Ochi F, Fujiwara H, Tanimoto K, Asai H, Miyazaki Y, Okamoto S, Mineno J, Kuzushima K, Shiku H, Barrett J, Ishii E, Yasukawa M. Gene-modified human alpha\/beta-T cells expressing a chimeric CD16-CD3zeta receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy. Cancer Immunol Res. 2014;2(3):249\u201362.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"595_CR32","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/blood-2005-09-3775","volume":"107","author":"B Clemenceau","year":"2006","unstructured":"Clemenceau B, Congy-Jolivet N, Gallot G, Vivien R, Gaschet J, Thibault G, Vie H. Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood. 2006;107(12):4669\u201377.","journal-title":"Blood"},{"issue":"1","key":"595_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","volume":"74","author":"K Kudo","year":"2014","unstructured":"Kudo K, Imai C, Lorenzini P, Kamiya T, Kono K, Davidoff AM, Chng WJ, Campana D. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 2014;74(1):93\u2013103.","journal-title":"Cancer Res"},{"issue":"Supplement1","key":"595_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood-2019-123810","volume":"134","author":"J Munoz","year":"2019","unstructured":"Munoz J, Jaglowski S, McKinney MS, Isufi I, Stiff PJ, Sachs J, Ranger A, Harris P, Payumo F, Akard LP. A phase 1 study of ACTR087 in combination with Rituximab, in subjects with relapsed or refractory CD20-Positive B-Cell lymphoma. Blood. 2019;134(Supplement1):244\u2013244.","journal-title":"Blood"},{"key":"595_CR35","doi-asserted-by":"crossref","unstructured":"Branella GM, Spencer HT. Natural receptor- and ligand-based chimeric Antigen receptors: strategies using natural ligands and receptors for targeted cell killing. Cells 2021, 11(1).","DOI":"10.3390\/cells11010021"},{"issue":"5","key":"595_CR36","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.apsb.2023.02.004","volume":"13","author":"W Zhu","year":"2023","unstructured":"Zhu W, Wang Y, Lv L, Wang H, Shi W, Liu Z, Zhou M, Zhu J, Lu H. Universal chimeric fcgamma receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy. Acta Pharm Sin B. 2023;13(5):2071\u201385.","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"595_CR37","doi-asserted-by":"publisher","first-page":"112797","DOI":"10.1016\/j.celrep.2023.112797","volume":"42","author":"Y Cui","year":"2023","unstructured":"Cui Y, Yuan T, Wang Y, Zheng D, Qin L, Li S, Jiang Z, Lin S, Guo W, Wang Z, Liang Z, Li Y, Yao Y, Liu X, Tang Q, Tu HY, Zhang XC, Tang Z, Wong N, Zhang Z, Qin D, Thiery JP, Xu K, Li P. T lymphocytes expressing the switchable chimeric fc receptor CD64 exhibit augmented persistence and antitumor activity. Cell Rep. 2023;42(7):112797.","journal-title":"Cell Rep"},{"issue":"4","key":"595_CR38","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s11427-022-2173-9","volume":"66","author":"Z Chen","year":"2023","unstructured":"Chen Z, Liu Y, Chen N, Xing H, Tian Z, Tang K, Rao Q, Xu Y, Wang Y, Wang M, Wang J. Loop CD20\/CD19 CAR-T cells eradicate B-cell malignancies efficiently. Sci China Life Sci. 2023;66(4):754\u201370.","journal-title":"Sci China Life Sci"},{"issue":"8","key":"595_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-021-00536-x","volume":"11","author":"N Chen","year":"2021","unstructured":"Chen N, Xu Y, Mou J, Rao Q, Xing H, Tian Z, Tang K, Wang M, Wang J. Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood Cancer J. 2021;11(8):144.","journal-title":"Blood Cancer J"},{"issue":"1","key":"595_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","volume":"12","author":"Y Xu","year":"2019","unstructured":"Xu Y, Liu Q, Zhong M, Wang Z, Chen Z, Zhang Y, Xing H, Tian Z, Tang K, Liao X, Rao Q, Wang M, Wang J. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J Hematol Oncol. 2019;12(1):49.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"595_CR41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-020-00953-8","volume":"13","author":"R Gu","year":"2020","unstructured":"Gu R, Liu F, Zou D, Xu Y, Lu Y, Liu B, Liu W, Chen X, Liu K, Guo Y, Gong X, Lv R, Chen X, Zhou C, Zhong M, Wang H, Wei H, Mi Y, Qiu L, Lv L, Wang M, Wang Y, Zhu X, Wang J. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):122.","journal-title":"J Hematol Oncol"},{"issue":"7918","key":"595_CR42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, Li P, Lin JX, Escuin-Ordinas H, Da T, Kremer SV, Sun AL, Castelli S, Agarwal S, Scholler J, Song D, Rommel PC, Radaelli E, Young RM, Leonard WJ, Ribas A, June CH, Garcia KC. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature. 2022;607(7918):360\u20135.","journal-title":"Nature"},{"key":"595_CR43","doi-asserted-by":"crossref","unstructured":"Guedan S, Posey AD Jr., Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, Young RM, June CH. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 2018, 3(1).","DOI":"10.1172\/jci.insight.96976"},{"issue":"9","key":"595_CR44","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","volume":"21","author":"SA Vardhana","year":"2020","unstructured":"Vardhana SA, Hwee MA, Berisa M, Wells DK, Yost KE, King B, Smith M, Herrera PS, Chang HY, Satpathy AT, van den Brink MRM, Cross JR, Thompson CB. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;21(9):1022\u201333.","journal-title":"Nat Immunol"},{"issue":"26","key":"595_CR45","first-page":"3153","volume":"141","author":"ME Selli","year":"2023","unstructured":"Selli ME, Landmann JH, Terekhova M, Lattin J, Heard A, Hsu YS, Chang TC, Chang J, Warrington J, Ha H, Kingston N, Hogg G, Slade M, Berrien-Elliott MM, Foster M, Kersting-Schadek S, Gruszczynska A, DeNardo D, Fehniger TA, Artyomov M, Singh N. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction. Blood. 2023;141(26):3153\u201365.","journal-title":"Blood"},{"issue":"7925","key":"595_CR46","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","volume":"609","author":"J Carnevale","year":"2022","unstructured":"Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O\u2019Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibanez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature. 2022;609(7925):174\u201382.","journal-title":"Nature"},{"issue":"3","key":"595_CR47","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1158\/1078-0432.CCR-20-2007","volume":"27","author":"DM Collins","year":"2021","unstructured":"Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O\u2019Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O\u2019Byrne KJ, Hasmann M, Bossenmaier B, O\u2019Donovan N, Crown J. Effects of HER Family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast Cancer. Clin Cancer Res. 2021;27(3):807\u201318.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"595_CR48","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1158\/1535-7163.MCT-09-1171","volume":"9","author":"NA O\u2019Brien","year":"2010","unstructured":"O\u2019Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O\u2019Donovan N, Slamon DJ. Activated phosphoinositide 3-kinase\/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther. 2010;9(6):1489\u2013502.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"595_CR49","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/2326-6066.CIR-22-0423","volume":"11","author":"D Rasoulouniriana","year":"2023","unstructured":"Rasoulouniriana D, Santana-Magal N, Gutwillig A, Farhat-Younis L, Tal L, Amar S, Milyavsky M, Muddineni S, Solomon N, Shpilt H, Dotan S, Pilpel N, Waskow C, Feinmesser M, Rider P, Carmi Y. T cells expressing a modified FcgammaRI exert antibody-dependent cytotoxicity and overcome the limitations of CAR T-cell therapy against solid tumors. Cancer Immunol Res. 2023;11(6):792\u2013809.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"595_CR50","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1002\/ijc.32618","volume":"146","author":"R Arriga","year":"2020","unstructured":"Arriga R, Caratelli S, Lanzilli G, Ottaviani A, Cenciarelli C, Sconocchia T, Spagnoli GC, Iezzi G, Roselli M, Lauro D, Coppola A, Dotti G, Ferrone S, Sconocchia G. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab. Int J Cancer. 2020;146(9):2531\u20138.","journal-title":"Int J Cancer"},{"issue":"16","key":"595_CR51","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","volume":"113","author":"P Bruhns","year":"2009","unstructured":"Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716\u201325.","journal-title":"Blood"},{"key":"595_CR52","doi-asserted-by":"crossref","unstructured":"Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. Role of Fcgamma receptors in HER2-targeted breast cancer therapy. J Immunother Cancer 2022, 10(1).","DOI":"10.1136\/jitc-2021-003171"},{"issue":"1","key":"595_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34\u201347.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"595_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","volume":"24","author":"F Galvez-Cancino","year":"2024","unstructured":"Galvez-Cancino F, Simpson AP, Costoya C, Matos I, Qian D, Peggs KS, Litchfield K, Quezada SA. Fc\u03b3 receptors and immunomodulatory antibodies in cancer. Nat Rev Cancer. 2024;24(1):51\u201371.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"595_CR55","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nri2803","volume":"10","author":"G de Saint Basile","year":"2010","unstructured":"de Saint Basile G, Menasche G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol. 2010;10(8):568\u201379.","journal-title":"Nat Rev Immunol"},{"issue":"7897","key":"595_CR56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, Lundh S, Pruteanu-Malinici I, Nobles CL, Maji S, Frey NV, Gill SI, Loren AW, Tian L, Kulikovskaya I, Gupta M, Ambrose DE, Davis MM, Fraietta JA, Brogdon JL, Young RM, Chew A, Levine BL, Siegel DL, Alanio C, Wherry EJ, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602(7897):503\u20139.","journal-title":"Nature"},{"issue":"1","key":"595_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40364-023-00509-1","volume":"11","author":"H Dabiri","year":"2023","unstructured":"Dabiri H, Safarzadeh Kozani P, Habibi Anbouhi M, Mirzaee Godarzee M, Haddadi MH, Basiri M, Ziaei V, Sadeghizadeh M, Hajizadeh Saffar E. Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies. Biomark Res. 2023;11(1):67.","journal-title":"Biomark Res"},{"key":"595_CR58","doi-asserted-by":"publisher","first-page":"878209","DOI":"10.3389\/fimmu.2022.878209","volume":"13","author":"G Lopez-Cantillo","year":"2022","unstructured":"Lopez-Cantillo G, Uruena C, Camacho BA, Ramirez-Segura C. CAR-T cell performance: how to improve their persistence? Front Immunol. 2022;13:878209.","journal-title":"Front Immunol"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00595-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T10:38:05Z","timestamp":1736937485000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00595-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["595"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00595-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4777567\/v1","asserted-by":"object"}]},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"21 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}